Keyphrases
Adjuvant Immunotherapy
10%
Adjuvant Therapy
8%
Adoptive Cell Therapy
21%
Advanced Melanoma
19%
Anti-PD-1
23%
Anti-PD-1 Therapy
11%
BRAF Inhibitor (BRAFi)
10%
Checkpoint Inhibitors
32%
Clinical Efficacy
8%
Clinical Outcomes
7%
Clinical Response
10%
Clinical Trials
14%
Complete Response
9%
Confidence Interval
13%
Cyclophosphamide
8%
Dendritic Cell Vaccine
27%
Denmark
13%
Early Identification
10%
Epitope
9%
Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography
10%
Fluorodeoxyglucose Positron Emission Tomography/computed Tomography
8%
Immune Checkpoint Inhibitors
26%
Immune Response
10%
Immune-related Adverse Events
7%
Improved Survival
7%
Indoleamine 2,3-dioxygenase 1 (IDO1)
10%
Interleukin-2
8%
Ipilimumab
10%
Melanoma
48%
Melanoma Patients
13%
Metastatic Melanoma
100%
Metronomic Cyclophosphamide
10%
Modern Treatment
7%
Monotherapy
11%
National Cohort Study
8%
Nivolumab
20%
Overall Survival
10%
Patient Demographics
7%
Patient Survival
11%
Phase II Trial
7%
Programmed Death-ligand 1 (PD-L1)
14%
Progression-free Survival
7%
Pseudoprogression
10%
Real Patients
13%
Real-world Impact
11%
Recurrence-free Survival
8%
Stage III-IV
7%
T Cells
9%
Tumor-infiltrating Lymphocytes
24%
Vaccination
9%
Medicine and Dentistry
Adjuvant Therapy
5%
Adverse Event
11%
Antigen Specificity
6%
Biological Marker
11%
Brain Metastasis
6%
Cell Therapy
21%
Clinical Trial
10%
Cohort Analysis
6%
Cohort Study
5%
Combination Therapy
10%
Computer Assisted Tomography
6%
CTLA-4
6%
Cytotoxic T-Cell
9%
Dendritic Cell
18%
Disease
12%
Fluorine-18
16%
Fluorodeoxyglucose
16%
Heart Left Ventricle Ejection Fraction
5%
Immune Checkpoint Inhibitor
20%
Immune Response
9%
Immunocompetent Cell
8%
Immunogenicity
5%
Immunotherapy
27%
Indoleamine 2,3 Dioxygenase
5%
Infusion
6%
Interleukin 2
7%
Long Term Survival
6%
Lymphocyte
5%
Malignant Neoplasm
13%
MEK Inhibitor
6%
Metastatic Melanoma
86%
Monotherapy
9%
Neoplasm
12%
Nivolumab
10%
Nodular Melanoma
71%
Odds Ratio
5%
Overall Survival
13%
Patient Population
7%
Phase II Trials
6%
Positron Emission Tomography
5%
Positron Emission Tomography-Computed Tomography
17%
Progression Free Survival
13%
Recurrent Disease
16%
Synapsin I
7%
Systematic Review
5%
T Cell
27%
T-Cell Response
5%
Transfer Cell
5%
Tumor Infiltrating Lymphocyte
24%
Tumor Regression
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
13%
Biological Marker
10%
Cardiotoxicity
5%
Castration Resistant Prostate Cancer
5%
Clinical Trial
7%
Cohort Study
10%
Combination Therapy
14%
Cyclophosphamide
10%
Cytotoxic T Lymphocyte Antigen 4
7%
Dendritic Cell Vaccine
6%
Disease
20%
Docetaxel
5%
Enterocolitis
5%
Epileptic Absence
8%
Epitope
5%
Feces microflora
5%
Fluorine 18
5%
Fluorodeoxyglucose
6%
Hepatotoxicity
5%
Immune Checkpoint Inhibitor
23%
Immunotherapy
28%
Indoleamine 2,3 Dioxygenase
10%
Interleukin 2
6%
Ipilimumab
9%
Long Term Survival
5%
Lung Cancer
5%
Malignant Neoplasm
12%
Melanoma
62%
Metastatic Colorectal Cancer
5%
Metastatic Melanoma
68%
Metastatic Uvea Melanoma
5%
Mitogen Activated Protein Kinase Kinase Inhibitor
6%
Monotherapy
11%
Neoplasm
13%
Nivolumab
20%
Overall Survival
17%
Phase II Trials
6%
Progression Free Survival
18%
Recurrent Disease
14%
Skin Manifestation
5%
Tofacitinib
5%
Vaccination Policy
19%
